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Background: Fibromyalgia (FM) is a pain condition with associated symptoms contributing to distress. The
Fibromyalgia Survey Diagnostic Criteria and Severity Scale (FSDC) is a patient-administered questionnaire assessing
diagnosis and symptom severity. Locations of body pain measured by the Widespread Pain Index (WPI), and the
Symptom Severity scale (SS) measuring fatigue, unrefreshing sleep, cognitive and somatic complaints provide a
score (0–31), measuring a composite of polysymptomatic distress. The reliability and validity of the translated
French version of the FSDC was evaluated.
Methods: The French FSDC was administered twice to 73 FM patients, and was correlated with measures of
symptom status including: Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire (HAQ), McGill
Pain Questionnaire (MPQ), and a visual analogue scale (VAS) for global severity and pain. Test-retest reliability,
internal consistency, and construct validity were evaluated.
Results: Test-retest reliability was between .600 and .888 for the 25 single items of the FSDC, and .912 for the total
FSDC, with all correlations significant (p < 0.0001). There was good internal consistency measured by Cronbach’s
alpha (.846 for FSDC assessment 1, and .867 for FSDC assessment 2). Construct validity showed significant
correlations between the FSDC and FIQ 0.670, HAQ 0.413, MPQ 0.562, global VAS 0.591, and pain VAS 0.663
(all p<0.001).
Conclusions: The French FSDC is a valid instrument in French FM patients with reliability and construct validity. It is
easily completed, simple to score, and has the potential to become the standard for measurement of
polysymptomatic distress in FM.
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The cornerstone symptom of fibromyalgia (FM) is chronic
widespread pain, with presence of associated symptoms of
fatigue, unrefreshing sleep, cognitive dysfunction, and a
variety of somatic symptoms that may be present to vari-
able degree in an individual patient [1,2]. It is this com-
bination of symptoms that constitutes the overall suffering
or distress of patients with chronic pain conditions or* Correspondence: mary-ann.fitzcharles@muhc.mcgill.ca
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distribution, and reproduction in any mediumFM. To date, there is no consensus regarding the ideal
measurement to assess symptom severity in FM, or to fol-
low patients regarding outcome or change in symptoms.
The only questionnaire that is disease specific for FM
and addresses a number of domains for this condition is
the Fibromyalgia Impact Questionnaire (FIQ), although
with criticism that it does not fully address all aspects of
FM, may not be sufficiently sensitive to change, and is
complex to score [3,4]. Other assessments for FM
patients have focused on individual symptoms such as
pain (i.e. visual analogue scale [VAS], McGill Pain Ques-
tionnaire [MPQ], Pain Disability Index [PDI]), fatiguetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and mood (i.e. Hospital Anxiety and Depression scale
[HADS]), but all used almost entirely in the research setting
[3,5-9]. There is therefore a need for an assessment tool
that may be easily applied in both the clinical and research
setting, is simple to score, and gives meaningful informa-
tion about the overall status of a patient with FM.
The Fibromyalgia Survey Diagnostic Criteria and Se-
verity Scale (FSDC) is a patient administered question-
naire that captures the key symptoms of FM, assesses
symptom severity, and has the potential to be a useful
instrument that can be applied in clinical care [10,11].
However, the diagnosis requires a medical examination
to rule out other somatic diseases that could sufficiently
explain the symptoms. The FSDC has been validated in
English speaking patients with FM as well as Japanese
patients with and without FM, and assesses the locations
of body pain as measured by the Widespread Pain Index
(WPI), and the associated symptom severity (SS) of fa-
tigue, unrefreshing sleep, cognitive complaints, and som-
atic symptoms [10,12]. The sum of the WPI and the SS
provides a score (0–31) which is a measurement of
symptom severity representing polysymptomatic distress.
In this current study we report on the validity and reli-
ability of a French translated version of the FSDC in a
tertiary clinic population of FM patients.
Methods
Study design
Eighty francophone patients with FM were invited to
participate in this study, 7 of whom did not fully
complete the questionnaires. Therefore, the study sam-
ple comprised 73 patients with an existing diagnosis of
FM, usually made by a family physician and confirmed
as a clinical diagnosis by a rheumatologist. Fifty-nine
consecutive patients are current participants in a pro-
spective cohort study in a multidisciplinary pain centre.
The remaining 14 participants, members of a patient
support group, were assessed by the study rheumatolo-
gist but were unable to participate in the cohort study
due to distance from the study centre, and did not differ
from the cohort study participants. All patients provided
informed consent and ethical approval was obtained
from the institutional review board of the Montreal
General Hospital.
Study procedure
At the time of the first assessment the following infor-
mation was obtained: demographic and disease related
information, questionnaires assessing symptoms and
function associated with FM, and the FSDC. All ques-
tionnaires were validated French language versions with
the exception of the FSDC. The patients were asked to
complete the FSDC on a second occasion, within 7 days,and the questionnaire was returned by mail. If not
returned, the study participant was prompted with a
telephone call, and if the questionnaire was not returned
within 2 weeks, the participant was counted as a study
withdrawal.
Assessment tools
Symptoms and physical functioning
Patients completed the FIQ, a validated disease specific
instrument assessing the health status of patients with
FM [3]. The FIQ is commonly used as a primary end-
point in clinical trials of FM. It consists of 19 subscales
assessing physical function, number of days feeling bad,
work missed, job ability, pain, fatigue, morning tiredness,
stiffness, anxiety and depression. The maximum score
for the FIQ is 100, with higher values indicating greater
severity. Functional status was also measured with the
Health Assessment Questionnaire disability index (HAQ)
[13]. Fatigue and patient global assessment of disease se-
verity were assessed by a 10 cm VAS for each parameter.
Pain assessment
Pain was assessed by a number of parameters. Pain in-
tensity was measured by a 10 cm VAS. Pain quality was
measured by means of the MPQ, a validated question-
naire comprising 78 descriptor words arranged into 20
subgroups and measuring the sensory, affective, eva-
luative, and miscellaneous components of pain [6].
Patients are asked to circle the word from each sub-
group which most accurately describes their pain. The
total MPQ intensity score is calculated by summing the
total number of words weighted by each word’s rank
order within its subcategory [6]. Pain-related interfer-
ence with role functioning was measured with the Pain
Disability Index (PDI), a validated generic measure of
function applicable to varied painful conditions with
measures in 7 areas (occupational, home/family, recre-
ational, social, sexual, activities of daily living and life
support), all rated on 11-point Likert type scale (0, no
disability, 10, complete disability). The maximum score
is 70, with higher score indicating greater severity [7,14].
A manikin of the body with a front and back view was
shaded to indicate location of pain. This was scored
according to the quantitative method recommended by
Staud and colleagues that measures a total of 50 areas
(26 back and 24 front)[15].
Fibromyalgia Survey Diagnostic Criteria (FSDC)
The FSDC is a patient administered questionnaire com-
prising 3 sections [10]. The first section contains 3 ques-
tions on symptoms of fatigue, cognitive problems, and
unrefreshing sleep during the past week, each of which is
scored by a Likert format from 0 (no problem) to 3
(severe: continuous, life-disturbing problems). The scores
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section comprises 3 questions with a positive or negative
response for the following somatic complaints occurring
during the past 6 months, abdominal pain or cramps, de-
pression, and headache, with a maximum score of 3. The
sum of section 1 and 2 provides a Symptom Severity
Score (SS), with a range from 0–12. The third section is a
measurement of the Widespread Pain Index (WPI) and is
completed by identifying body areas where pain or ten-
derness was felt during the previous 7 days, with a total
of 19 body areas identified as follows: shoulder girdle (left
and right), upper arm (left and right), lower arm (left and
right), hip (left and right), upper leg(left and right), lower
leg (left and right), jaw (left and right), chest, abdomen,
upper back, lower back, and neck. The maximum score
for the WPI section is 19. The fibromyalgianess scale
(FS) is defined as the sum of the (0–19) WPI and the
6-item (0–12) SS scale. It has a range of 0–31.Table 1 Sample characteristics for 73 FM patients
Characteristics
Age, years 52 ± 9
Duration FM years 12 ± 12
Pain , VAS 6.0 ± 2.8
MPQ 40 ± 15
PDI 32 ± 17
Body Map 25 ± 12
Patient global severity, VAS 5.7 ± 2.5
FIQ 60 ± 21
HAQ 1.1 ± 0.78
LEGEND: FM: Fibromyalgia, VAS: Visual Analog Scale, MPQ: McGill Pain.
Questionnaire, PDI: Pain Disability Index, FIQ: Fibromyalgia Impact
Questionnaire, HAQ: Health Assessment Questionnaire.Translation of the FSDC
The translation protocol used to translate the FSDC is
based on methodology that has been previously pub-
lished [16,17] and applied to obtain Canadian French
versions of evaluation instruments [18]. With the per-
mission of the authors, the FSDC was translated into
French as follows. We obtained two initial forward
translations of the instrument into French by two bilin-
gual individuals, one with health-related experience and
the other from the lay public, whose first language is
French. The two forward translations were then back-
translated into English by two bilingual individuals, one
with health-related experience and the other from the
lay public, whose mother tongue is English. The original
version, the two French forward translations, and the
two English back translations were reviewed by a com-
mittee composed of two investigators, one whose
mother tongue is French and the other English, and one
of the individuals involved in the back translation. The
committee members worked by consensus to finalize a
single French version of the FSDC, ensuring the concep-
tual and linguistic equivalence of the two versions.
The experimental version of the instrument was tested
on a sample of 5 bilingual patients to ensure clarity and
comprehension. They completed both the French and
English versions of the instrument, in random order, and
indicated if they found any instructions or items difficult
or ambiguous. An investigator was present for cognitive
debriefing. Any items for which difficulties were encoun-
tered in the French translation, but not in the original
version, were re-worded by the investigators. We assessed
the test-re-test reliability of the French Canadian version
by administering the instrument to a group of French-
speaking patients twice within a 1 week period.Statistical analysis
Test-retest reliability of the FSDC was assessed with
Pearson’s correlation coefficients. To assess internal
reliability, an analysis of internal consistency using
Cronbach’s coefficient α was performed with measure-
ment of .9 < α ≥ .8 considered as representing good
internal consistency. To test construct validity we
hypothesized a strong to moderate relationship between
the FSDC and other measures of symptom severity in FM
including the FIQ and HAQ, and symptoms of fatigue,
pain, and global status. Strength of correlation was graded
according to the recommendation of Cohen as follows: 1.
Moderate correlation coefficient (.30 to .49) 2. Strong cor-
relation coefficient (.50 to 1.0) [19].Results
Population characteristics
The study sample consisted of 73 francophone patients,
mean age 52 ± 9 years, 67(92%) female, and mean disease
duration 12 ± 12 years. The 7 withdrawn patients did not
differ demographically from the study sample. Demo-
graphic and disease related characteristics of the study
sample are shown in Table 1, with scores on para-
meters of symptom and functional complaints compar-
able to other populations of patients with FM. The
FSDC was easy to complete with an average comple-
tion time of 2 minutes, and the average scoring time
was 1 minute.Correlation analysis
Test-retest reliability was between .600 and .888 for the
25 single items of the FSDC, and .912 for the total
FSDC, with all correlations significant (p < 0.0001)
(Table 2). Cronbach’s alpha was .846 for FSDC assess-
ment 1, and .867 for FSDC assessment 2 indicating good
internal consistency for both assessments.
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In order to test construct validity the Spearman correlation
coefficients between the total FSDC and study question-
naires were calculated. Construct validity showed significant
correlations between the total FSDC and the total FIQ
0.670, HAQ 0.413, MPQ 0.562, global VAS 0.591 and pain
VAS 0.663 (all p<0.001). The individual subcomponents of
the FSDC including measurements for pain, fatigue, cogni-
tive problems, awakening unrefreshed from sleep, and
symptoms of abdominal pain, depression and headache
were correlated with measurements of pain (pain VAS,
MPQ, PDI, Body Map and FIQ pain), and fatigue, restful-
ness, and depression as measured by the FIQ (Table 3).
Discussion
In this study, we have demonstrated that the French ver-
sion of the FSDC is a reliable instrument for measure-
ment of symptom severity in patients with FM, with
test-retest reliability coefficients ranging from .600 to
.912, for both the individual component as well as totalTable 2 Paired samples correlations for the individual
components of the FSDC in 73 FM patients
Fatigue .667
Trouble thinking or remembering .709
Waking up tired (unrefreshed) .635







Upper arm L .852
Upper arm R .791
Lower arm L .712
Lower arm R .755
Upper leg L .724
Upper leg R .634
Lower leg L .716










Survey total /31 .912scores. We have also further demonstrated validity of
this instrument with good correlation between the FSDC
and other measures used to assess symptom complaint
in FM. Therefore this study, conducted in a French
speaking population of FM patients, further supports the
usefulness of the FSDC in FM patients.
The FSDC was devised following the reevaluation of
diagnostic criteria for FM, acknowledging that the symp-
tomology of this syndrome extends beyond that of only
body pain [10,11]. As FM presents a spectrum of sever-
ity rather than uniquely an all or none diagnosis, the
composite and severity of symptoms, rather than solely a
report of pain, should be addressed. Incorporating symp-
toms beyond pain will provide a more meaningful as-
sessment of the global impact of this condition in an
individual patient. Following the proposal for redefining
diagnostic criteria, the working group has proposed a se-
verity scale in order to grade severity of symptoms in a
patient with FM [10]. The FSDC sets out to address
these symptoms, with weighting equivalent to two thirds
for pain, and one third for other symptoms. The max-
imum score for the FSDC is 31, with 13 suggested as
a cutoff point to discriminate those with FM from
those without FM [10]. The FSDC has been validated in
English and in Japanese patients with FM, as well as
patients with non-FM rheumatic disease [10,12]. This
recognition of co associated symptoms with pain in FM
is in line with increased neurophysiologic understanding
of this condition [20].
When the new criteria for FM were proposed in 2010,
the questionnaire devised for diagnostic purposes was
originally completed both by the patient and physician
[11]. In order to enable the questionnaire to be used for
survey purposes and to introduce a severity scale, a fully
patient-completed questionnaire, the FSDC, was devel-
oped [10]. This questionnaire measures the overall distress
of FM and was previously termed the “fibromyalgianess
scale” [10,21]. This composite of symptoms is however not
unique to FM but may be applicable to patients with other
chronic pain conditions. We therefore propose that
the FSDC should now be renamed the “Polysymptomatic
Distress Scale” (PDS). We believe that this clarification will
simplify patient care. Further studies testing the validity of
the FSDC now named the PDS in other rheumatic diseases
and chronic pain conditions are required.
There are a number of points that require clarification.
There is currently no single measurement for symptom
severity in FM that is entirely comparable with the
FSDC. The two measures that most closely align with
the FSDC are the patient global assessment of disease
severity and the FIQ [3]. The FIQ has a functional as
well as a symptom component, but does not address
symptoms of cognition or other somatic symptoms,
whereas the FSDC measures only symptoms, and does
Table 3 Non-parametric Spearman’s ρ correlations between individual components of the FSDC and other measures
Individual measures of FSDC Pain-VAS MPQ PDI Body map FIQ- pain FIQ-fatigue FIQ-restfulness FIQ-depression
Pain .660*** .562*** .644*** .793*** .604*** .538*** .445*** .240*
Fatigue .414*** .214 .471*** .351** .570*** .546*** .382** .066
Cognitive problems .347** .307** .398*** .461*** .487*** .355** .348** .080
Unrefreshing sleep .380*** .355** .465*** .241* .557*** .563*** .423*** .166
Abdominal pain .051 .060 .185 .025 .117 .065 -.084 -.213
Depression -.112 .069 .010 -.178 -.123 -.055 .020 .390***
Headache .220 .099 .265* .254* .259* .187 .022 -.091
LEGEND: * p≤ 0.05, **p≤ 0.01, ***p≤ 0.001.
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assessed the comparable individual components of pain,
fatigue and sleep disturbance for the FIQ and FSDC in
order to make direct comparisons. It is also acknowl-
edged that the specific questions regarding pain, sleep
disturbance, mood, and fatigue are nuanced differently
in the FIQ and FSDC and could be open to different
interpretations. However, even with these considerations,
both the total FIQ and patient global assessment of dis-
ease severity, as well as individual measures of pain, fa-
tigue, and unrefreshing sleep, correlated well with the
FSDC indicating construct validity for assessment in
patients with FM. An additional consideration is that all
patients in our study had an established diagnosis of
FM. It could be argued that these patients might express
symptom severity at the extreme end of the spectrum
and therefore would be more likely to show construct
validity. Our patients are however similar to those
reported by other authors [22].
We have also demonstrated validity for the pain com-
ponent of the FSDC when compared to a number of
other measures of pain assessment including a numerical
count of pain areas marked on a body map, pain VAS,
and MPQ. It is notable that the pain component of the
FSDC, namely the WPI, assesses only the location of
body pain, whereas the pain VAS assesses intensity, and
the MPQ assesses mostly the emotional impact of pain.
It is therefore interesting to note that the different pain
measures correlated well with the WPI. This might sug-
gest that the location or diffuseness of pain in FM may
be associated with severity from the patient viewpoint.
An important consideration is the simplicity of the
FSDC from the patient viewpoint, and the ease of scoring
for the investigator. A questionnaire that requires simple
numerical addition without need for any adjustments
represents an attractive tool that might even become use-
ful in clinical practice. The whole questionnaire is on a
single page, allowing for a first impression as one that is
less challenging than a lengthier document. Even though
this questionnaire is remarkably simple and easy to ad-
minister in English, we followed a rigorous translation
protocol and did not identify any important culturaladaptations that required attention. We do acknowledge
the limitation of this study which was conducted at a sin-
gle tertiary care centre and therefore recommend that
further testing of the FSDC should be done at the pri-
mary care level.Conclusion
In conclusion, this new diagnostic and severity scale for
FM performed well in the French translated version for
patients with a diagnosis of FM. The FSDC, previously
termed the “Fibromyalgianess Scale” which we propose
should be renamed the “Polysymptomatic Distress Scale”
(PDS), still requires further validation in other settings
for patients with FM, as well as testing in other groups
of patients with pain. Furthermore, the FSDC requires
correlation with other meaningful and objective mea-
sures of function and disability in FM patients, such as
sick-leave. If shown to be sensitive to change, this sever-
ity scale could be a useful tool for assessing outcome in
both the clinical as well as the study setting. This ques-
tionnaire is unique in its simplicity, with completion by
patients within a few minutes, and time to score mea-
sured as less than one minute. This tool has the potential
to become the standard for measurement of symptom
severity in FM and other chronic pain conditions.Additional file
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